Intriguingly, it is shown that chronic CML patients who relapsed after initially successful imatinib treatment (many with acquisition of BCR-ABL mutations) demonstrate gene expression signatures more similar to advanced disease than chronic phase [18], and may have reduced differentiation as well. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.